

8 September 2009

Synairgen plc ('Synairgen' or the 'Company')

Grant of options

On 7 September 2009 Richard Marsden, Chief Executive Officer of Synairgen, was granted options over 605,000 ordinary shares of 1 pence each ("Ordinary Shares") in the Company under the Company's Long-Term Incentive Plan (the "LTIP") at an exercise price of 1 pence per share.

Mr Marsden's holding in options over Ordinary Shares has therefore increased to 1,670,459 representing approximately 2.80 per cent. of the issued ordinary share capital of the Company.

On 7 September 2009 John Ward, Finance Director of Synairgen, was granted options over 550,000 Ordinary Shares in the Company under the Company's LTIP at an exercise price of 1 pence per share.

Mr Ward's holding in options over Ordinary Shares has therefore increased to 1,226,532, representing approximately 2.05 per cent. of the issued ordinary share capital of the Company.

On 7 September 2009 Dr Phillip Monk, Chief Scientific Officer of Synairgen, was granted options over 414,625 Ordinary Shares in the Company under the Company's LTIP at an exercise price of 1 pence per share.

Dr Monk's holding in options over Ordinary Shares has therefore increased to 554,064, representing approximately 0.93 per cent. of the issued ordinary share capital of the Company.

On 7 September 2009 Paul Clegg, Non-executive Director of Synairgen, was granted options over 250,000 Ordinary Shares in the Company under the Synairgen Qualifying Non-Employee Share Option Plan 2009 at an exercise price of 20 pence per share, representing approximately 0.42 per cent. of the issued ordinary share capital of the Company.

For further information, please contact:

Synairgen plc

Richard Marsden, Chief Executive Officer
John Ward, Finance Director

Tel: + 44 (0) 23 8051 2800

Matrix Corporate Capital

Alastair Stratton
Anu Tayal

Tel: + 44 (0) 20 3206 7000